These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 791322)

  • 21. The comparative pharmacology of cyclophosphamide and ifosfamide.
    Colvin M
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):2-7. PubMed ID: 6761865
    [No Abstract]   [Full Text] [Related]  

  • 22. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pyridoxine on the distribution of chloramphenicol and its residues in the chicken.
    Atef M; Hanafy MS; abd el-Aziz MI
    Br Poult Sci; 1993 Mar; 34(1):161-6. PubMed ID: 8467395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone.
    Korhonen T; Turpeinen M; Tolonen A; Laine K; Pelkonen O
    J Steroid Biochem Mol Biol; 2008 May; 110(1-2):56-66. PubMed ID: 18356043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological interference of glibornuride with sulfaphenazole, phenylbutazone, and phenprocoumon in man].
    Eckhardt W; Rudolph R; Sauer H; Schubert WR; Undeutsch D
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2212. PubMed ID: 4679251
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.
    Jamieson D; Lee J; Cresti N; Jackson R; Griffin M; Sludden J; Verrill M; Boddy AV
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):667-74. PubMed ID: 25055937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide.
    Mouridsen HT; Faber O; Skovsted L
    Cancer; 1976 Feb; 37(2):665-70. PubMed ID: 1253102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1979 Sep; 8(3):209-17. PubMed ID: 497087
    [No Abstract]   [Full Text] [Related]  

  • 29. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
    Donelli MG; Bartosek I; Guaitani A; Martini A; Colombo T; Pacciarini MA; Modica R
    Cancer Treat Rep; 1976 Apr; 60(4):395-401. PubMed ID: 1277213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.
    Ren S; Yang JS; Kalhorn TF; Slattery JT
    Cancer Res; 1997 Oct; 57(19):4229-35. PubMed ID: 9331082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biotransformation and biologically active metabolites of cyclophosphamide].
    Roth J
    Hippokrates; 1974 May; 45(2):260-1. PubMed ID: 4845797
    [No Abstract]   [Full Text] [Related]  

  • 32. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulphaphenazole, streptomycin and sulphaphenazole combination, trimethoprim, and erythromycin in the treatment of chancroid.
    Kumar B; Sharma VK; Bakaya V
    Genitourin Med; 1990 Apr; 66(2):105-7. PubMed ID: 2187791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
    Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
    J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of cyclophosphamide in Kenyan Africans.
    Juma F; Ogada T
    Br J Clin Pharmacol; 1983 Jul; 16(1):61-3. PubMed ID: 6882623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On the activation of cyclophosphamide in man and animals].
    Brock N
    Prensa Med Argent; 1971 Jan; 57(48):2170-8. PubMed ID: 5091404
    [No Abstract]   [Full Text] [Related]  

  • 37. PLasma half-life and urinary excretion of cyclophosphamide in children.
    Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
    Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism of high doses of cyclophosphamide.
    Milsted RA; Jarman M
    Cancer Chemother Pharmacol; 1982; 8(3):311-3. PubMed ID: 7127662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.
    Jarman M; Milsted RA; Smyth JF; Kinas RW; Pankiewicz K; Stec WJ
    Cancer Res; 1979 Jul; 39(7 Pt 1):2762-7. PubMed ID: 445480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased half life of cyclophosphamide in patients under continual treatment.
    D'Incalci M; Bolis G; Facchinetti T; Mangioni C; Morasca L; Morazzoni P; Salmona M
    Eur J Cancer (1965); 1979 Jan; 15(1):7-10. PubMed ID: 421718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.